

Primary objective
•
To evaluate the efficacy of cediranib by
measuring the
percentage change in the
sum of target marker lesion diameters
from randomisation to week 24
compared to placebo
Secondary objectives
•
Progression-free survival
•
Overall survival
•
Safety
•
Tolerability
Judson I, et al. Novemeber 10th 2017; CTOS 2017 - USA